Publications by authors named "Richard Eek"

Claim this Profile
T
The Utility of Molecular Tumor Profiling for Patients With Advanced or Rare Cancer in a Regional Australian Setting.
Natalie Chilko, Ortis Estacio, Christopher Steer, Kerrie Clarke, Richard Eek

Asia Pac J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.
Slavisa Ninkovic, Simon J Harrison, Je-Jung Lee, Nick Murphy, Jae Hoon Lee, Richard Eek

Haematologica· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
Sarwan Bishnoi, Dusan Kotasek, Morteza Aghmesheh, Thomas Yau, Rasha Cosman, Richard Eek

Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, Pier Luigi Zinzani, Andre Goy, Richard Eek

Haematologica· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.
Marliese Alexander, Sam Harris, Craig Underhill, Javier Torres, Sharad Sharma, Richard Eek

JAMA Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Seroprevalence in a Cohort of International Travellers Returning to Rural Australia: Enablers and Barriers to Containment of COVID-19.
Justin Jackson, Chun Chan, Jacqueline McBurnie, Gina La Hera-Fuentes, John Burston, Richard Eek

Aust N Z J Public Health· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Richard Eek

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.
Constantine S Tam, Hang Quach, Andrew Nicol, Xavier Badoux, Hannah Rose, Richard Eek

Blood Adv· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnovas, Richard Eek

Leukemia· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.
Melita Kenealy, Mark Hertzberg, Warwick Benson, Kerry Taylor, Ilona Cunningham, Richard Eek

Haematologica· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnovas, Richard Eek

Lancet· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Cyrille Hulin, Andrew Belch, Chaim Shustik, Maria Teresa Petrucci, Ulrich Dührsen, Richard Eek

J Clin Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraluminal Superior Vena Cava Metastasis in a Patient With Poorly Differentiated Thyroid Carcinoma.
Caitlin Murphy, Heinrich Schwalb, Sam Berlangieri, Richard Eek

J Clin Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncology service initiatives and research in regional Australia.
Caitlin Murphy, Sabe Sabesan, Christopher Steer, Patsy Yates, Anne Booms, Richard Eek

Aust J Rural Health· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases.
Kristin Harris, Edward Chow, Liying Zhang, Galina Velikova, Andrea Bezjak, Richard Eek

Eur J Cancer· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines for CPD accreditation of the South African Society of Medical Oncology.
Raymond P Abratt, Richard W Eek, Louis Goedhals, Bernardo Rapoport, Coenraad F Slabber

S Afr Med J· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Richard Eek

J Clin Oncol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis